IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Mallinckrodt Plc (“Mallinckrodt” or the “Company”) (MNK). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of Mallinckrodt during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On November 9, 2015, Citron Research published a report that described the Company’s abuse of the pharmaceutical reimbursement system. The report claimed that Mallinckrodt has “significantly more downside” than rival Valeant Pharmaceuticals International, Inc.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.